MacroGenics Adds Two Independent Directors
Emil Kuriakose and Michael Vasconcelles join the clinical-stage biopharmaceutical company's Board of Directors.
Updated on Nov. 3, 2026 in People
MacroGenics has appointed Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., as independent directors to its Board of Directors, effective October 30, 2026. The appointments were announced November 3, 2026, by the Rockville-based company.
Why it matters
The additions bring board-level experience from oncology drug development and industry leadership to a company focused on antibody-based cancer therapeutics. For Rockville's biotech community, the appointments reflect the continued growth of the region's drug development sector.
Michael Vasconcelles brings approximately 35 years of experience across academic medicine, oncology, and executive leadership, while Emil Kuriakose has more than a decade in the biopharmaceutical industry. Committee roles and term lengths for both directors were not disclosed in the announcement.
The players
MacroGenics
A clinical-stage biopharmaceutical company focused on antibody-based cancer therapeutics, trading on NASDAQ under the ticker MGNX.
Emil Kuriakose, M.D.
A physician-executive who served as Chief Medical Officer of Terns Pharmaceuticals before its acquisition by Merck in 2026.
Michael Vasconcelles, M.D.
An oncology and drug development executive who previously led research and development at Day One Biopharmaceuticals and sits on the boards of Molecular Partners AG and Kura Oncology.
The details
Kuriakose previously served as Chief Medical Officer of Terns Pharmaceuticals, which Merck acquired in 2026. Vasconcelles most recently served as Head of Research and Development at Day One Biopharmaceuticals and currently sits on the boards of Molecular Partners AG and Kura Oncology, Inc. The appointments were announced through GlobeNewswire and take effect October 30, 2026.
Timeline
October 30, 2026: Board appointments of Kuriakose and Vasconcelles take effect.
November 3, 2026: MacroGenics announces the board appointments.
Market Landscape
The appointment of a former Terns Pharmaceuticals executive follows Merck's 2026 acquisition of the company, illustrating how senior talent from acquired biotech firms moves into board and leadership roles at other drug developers. Such moves are a common pattern in the oncology and clinical-stage biopharmaceutical sector, where experienced physician-executives are in steady demand.
For investors holding MacroGenics stock under the ticker MGNX, the expanded board adds experienced independent oversight of the company's cancer drug pipeline. The appointments do not change product availability or pricing for patients or customers.
The takeaway
Board changes at clinical-stage biotech companies often signal shifts in strategic focus, and readers tracking MacroGenics can watch future filings for committee assignments and pipeline updates tied to these new directors' expertise.
Further reading
For more on biotech leadership moves, explore People coverage in Rockville.
Source note: This article includes information reported by The Manila times.
